-
Nov 29, 2024 | 
onlinelibrary.wiley.com | Katherine Nelson |Richard Beasley |Allie Eathorne |Diane M. Mackle
Aim The Intensive Care Unit Randomised Trial Comparing Two Approaches to Oxygen Therapy Trial (ICU-ROX) compared conservative oxygen therapy with usual care in mechanically ventilated adults in Australian and New Zealand intensive care units. Dissemination focused on publication and presentation, with no targeted approach.
-
Jul 11, 2024 | 
erj.ersjournals.com | Michaela Donaghy |Mark Weatherall |Richard Beasley |Emma Ball
FootnotesThis is a post hoc analysis of a clinical trial prospectively registered at the Australian New Zealand Clinical Trials Registry with identifier number: ACTRN12611000184976. Ethics statement: All the patients provided written informed consent. Conflict of interest: The authors have no potential conflicts of interest to disclose.
-
Jun 20, 2024 | 
erj.ersjournals.com | Richard Beasley |Jonathan Noble |Mark Weatherall
Reply to P.J. McDowell and co-workers:We agree with P.J. McDowell and co-workers that the patients whose data are recorded in the UK Severe Asthma Registry (UKSAR) have, on average, more severe asthma than participants in randomised controlled trials (RCTs) of inhaled corticosteroid (ICS)/formoterol maintenance and reliever therapy (MART) [1, 2].
-
May 16, 2024 | 
erj.ersjournals.com | Mark Weatherall |Richard Beasley |Emma Ball |Michaela Donaghy
FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of Interest: All authors have nothing to disclose.
-
Mar 29, 2024 | 
digitalcommons.library.tmc.edu | Helen Reddel |Alvar Agusti |Gary Anderson |Richard Beasley
AbstractAsthma and chronic obstructive pulmonary disease (COPD) have overlapping clinical features and share pathobiological mechanisms but are often considered distinct disorders. Prospective, observational studies across asthma, COPD and asthma-COPD overlap are limited. NOVELTY is a global, prospective observational 3-year study enrolling ∼12 000 patients ≥12 years of age from primary and specialist clinical practices in 19 countries (ClinicalTrials.gov identifier: NCT02760329).
-
Mar 29, 2024 | digitalcommons.library.tmc.edu | Helen Reddel |Alvar Agusti |Gary Anderson |Richard Beasley
AbstractAsthma and chronic obstructive pulmonary disease (COPD) have overlapping clinical features and share pathobiological mechanisms but are often considered distinct disorders. Prospective, observational studies across asthma, COPD and asthma-COPD overlap are limited. NOVELTY is a global, prospective observational 3-year study enrolling ∼12 000 patients ≥12 years of age from primary and specialist clinical practices in 19 countries (ClinicalTrials.gov identifier: NCT02760329).
-
Feb 8, 2024 | 02222-5/abstract&sz=64)
thelancet.com | Thomas Hills |Mark Weatherall |Richard Beasley
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
-
Jan 25, 2024 | 
bjgp.org | Mark Levy |Richard Beasley |Bev Bostock |Toby Capstick
IntroductionResistance to changing clinical practice in response to scientific evidence is common.
-
Dec 14, 2023 | 
erj.ersjournals.com | Richard Beasley |Jonathan Noble |Mark Weatherall
FootnotesConflict of interest: R. Beasley has received institutional research funding from AstraZeneca, Cure Kids (NZ), Genentech and the Health Research Council of NZ, and personal fees from AstraZeneca, Avillion, Teva Pharmaceuticals and Cipla, outside the submitted work. R. Beasley is chair of the Asthma Foundation of New Zealand adolescent and adult asthma guidelines group. J. Noble and M. Weatherall have no conflicts of interest to declare. Received October 25, 2023. Accepted October 27, 2023.
-
Sep 7, 2023 | 
erj.ersjournals.com | Alberto Papi |Richard Beasley |Guy G. Brusselle |Courtney Coleman
FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
